ReviewJournal of cardiovascular translational research2020
Gender Differences in Cardiac Hypertrophy.
Review in Journal of cardiovascular translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 63 citations in OpenAlex.
- Resistance training improves cardiac function in older women: a randomized controlled trial.GeroScience · 2025Trial
- Cardiovascular Disease and Androgens: Clinical Trends, Potential Mechanisms, and Considerations for Engineering Solutions.Cardiovascular engineering and technology · 2026Review
- Optical coherence tomography angiography (OCTA) assessing microvascular and macrovascular health in healthy octogenarians.GeroScience · 2026Article
- Demographics and mortality trends of hypertensive heart failure in the United States, 2006-2020: Insights from the CDC WONDER database.The Journal of international medical research · 2026Observational
- Development of the Cardiovascular System During Adolescence.Advances in experimental medicine and biology · 2026Review
- Modeling the interplay of sex hormones in cardiac hypertrophic signaling.PLoS computational biology · 2025Article
- Estradiol is not protective against angiotensin II-induced hypertension in middle-aged ovariectomized rats.Physiological reports · 2025Article
- Ferritinophagy in cardiovascular diseases: mechanisms and potential therapy.Molecular and cellular biochemistry · 2025Review
- Healthy human induced pluripotent stem cell-derived cardiomyocytes exhibit sex dimorphism even without the addition of hormones.Stem cells (Dayton, Ohio) · 2025Article
- Understanding Sex Differences in Hypertrophic Cardiomyopathy Surgery: Insights From a Decade-Long Cohort Study From China.Journal of the American Heart Association · 2025Article
- 17-beta estradiol prevents cardiac myocyte hypertrophy by regulating mitochondrial E3 ubiquitin ligase 1.Cell death & disease · 2025Article
- Effects of sex and obesity on immune checkpoint inhibition-related cardiac systolic dysfunction in aged mice.Basic research in cardiology · 2025Article
- Sex differences in cardiac energetics in the rat ventricular muscle.Scientific reports · 2024Article
- Sex-Related Differences in the Prevalence of Classical, Non-Classical Risk Factors and Management of the Chronic Coronary Syndrome.Journal of clinical medicine · 2023Article
- Androgen Receptor and Cardiovascular Disease: A Potential Risk for the Abuse of Supplements Containing Selective Androgen Receptor Modulators.Nutrients · 2023Review
- Age and gender differences of basic electrocardiographic values and abnormalities in the general adult population; Tehran Cohort Study.BMC cardiovascular disorders · 2023Article
- Sex chromosome mechanisms in cardiac development and disease.Nature cardiovascular research · 2023Article
- Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.Frontiers in aging · 2023Article
- Age at menopause is inversely related to the prevalence of common gynecologic cancers: a study based on NHANES.Frontiers in endocrinology · 2023Article
- Respirasome Proteins Are Regulated by Sex-Hormone Interactions in the Brain.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac hypertrophy is an adaptive response to abnormal physiological and pathological stimuli, which can be classified into concentric and eccentric hypertrophy, induced by pressure overload or volume overload, respectively. In both physiological and pathological scenarios, females generally show a more favorable form of hypertrophy compared with their male counterparts. However once established, cardiac hypertrophy is a stronger risk factor for heart failure in females. Pre-menopausal women are better protected against cardiac hypertrophy compared with men, but this protection is abolished following menopause and is partially restored after estrogen replacement therapy. Estrogen exerts its protection by counteracting pro-hypertrophy signaling pathways, whereas androgen mostly plays an opposite role in cardiac hypertrophy. We here summarize the progress in the understanding of sexual dimorphisms in cardiac hypertrophy and highlight recent breakthroughs in the regulatory role of sex hormones and their intricate molecular networks, in order to shed light on gender-oriented therapeutic efficacy for pathological hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.